Ascentage Pharma Group International
AAPG- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002023311
No open-market purchases or sales by Ascentage Pharma Group International insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $263.5K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Ascentage Pharma Group International as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 8
- +1 vs. Q1 2026
- Shares held
- 15.0K
- −15.2K (−50.4%) vs. Q1 2026
- Total value
- $263.5K
- −$458.2K (−63.5%) vs. Q1 2026
- New holders
- 3
- 1 more added
- Sold out
- 2
- 2 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AAPG on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $263.5K |
| Q1 2026 | 7 | $721.7K |
| Q4 2025 | 12 | $1.25M |
| Q3 2025 | 14 | $3.69M |
| Q2 2025 | 12 | $3.22M |
| Q1 2025 | 6 | $5.21M |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Ascentage Pharma Group International; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | 13,841 | $243.0K | 0.00% | −2,215−13.8% | Reduced |
| Morgan Stanley | 919 | $16.1K | 0.00% | +421+84.5% | Added |
| Wells Fargo & Company | 200 | $3.51K | 0.00% | +200 | New |
| EverSource Wealth Advisors, LLC | 24 | $421 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 15 | $263 | 0.00% | −109−87.9% | Reduced |
| BlackRock, Inc. | 6 | $105 | 0.00% | +6 | New |
| Caitong International Asset Management Co., Ltd | 1 | $18 | 0.00% | +1 | New |
| Royal Bank of Canada | 6 | $0 | 0.00% | 00.0% | Unchanged |
| XY Capital Ltd | 0 | $0 | 0.00% | −13,014−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −518−100.0% | Sold out |